Truist Financial Corp Trims Stock Position in Alzamend Neuro, Inc. (NASDAQ:ALZN)

Truist Financial Corp cut its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 93.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 154,327 shares of the company’s stock after selling 2,160,580 shares during the quarter. Truist Financial Corp’s holdings in Alzamend Neuro were worth $137,000 at the end of the most recent quarter.

Alzamend Neuro Stock Performance

Alzamend Neuro stock opened at $0.62 on Thursday. The company’s 50 day simple moving average is $0.79 and its 200-day simple moving average is $0.95. The company has a market capitalization of $4.27 million, a price-to-earnings ratio of -0.63 and a beta of 0.12. Alzamend Neuro, Inc. has a 1 year low of $0.44 and a 1 year high of $11.91.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings results on Monday, March 25th. The company reported ($0.38) earnings per share (EPS) for the quarter.

Alzamend Neuro Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.